Evidence map›Paper›PMID 20401687›Full record

ReviewJournal of clinical immunology2010

Adoptive-transfer effects of intravenous immunoglobulin in autoimmunity.

Alan H Lazarus

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of clinical immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alan H LazarusThe Canadian Blood Services, Ottawa, ON, Canada. lazarusa@smh.toronto.on.ca
Canadian Blood Services · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous immunoglobulin (IVIG) is an effective treatment for a variety of autoimmune and inflammatory conditions. The mechanism of action of IVIG remains poorly understood, but a variety of theories have been suggested. Recent studies in murine models have indicated that some of the ameliorative effects of IVIG in autoimmunity can be repeated by the adoptive transfer of leukocytes that have been primed with IVIG. The active cell component within the leukocyte cell population in immune thrombocytopenia (ITP) was determined to be CD11c(+) dendritic cells. This review will highlight recent work in murine systems that indicates that the effects of IVIG can be adoptively transferred in some autoimmune diseases and inflammatory states.

Indexed as

Adoptive TransferAbortion, HabitualAnimalsAntigen-Antibody ComplexArthritis, ExperimentalAutoimmune DiseasesDendritic CellsDisease Models, AnimalFemaleFetal ResorptionImmunoglobulins, IntravenousInflammationLeukocytesMiceModels, ImmunologicalPregnancyAntigen-Antibody ComplexImmunoglobulins, IntravenousReceptors, IgG

Identifiers

PMID20401687
OpenAlexW1989702918

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.